Imatinib mesylate in children and adolescents with cancer.
作者： Ronald D. Barr
DOI: 10.1002/PBC.22484
关键词:
摘要: Imatinib is an inhibitor of the BCR–ABL fusion gene product that characterizes chronic myeloid leukemia (CML), and related tyrosine kinases c-KIT platelet-derived growth factor (PDGF) receptor. The drug now included as front-line therapy for CML Philadelphia chromosome-positive acute lymphoblastic in children adolescents, though valid concerns about serious late sequelae remain unresolved are important issues further study. European North American consortia have conducted phase I II clinical trials imatinib adolescents with brain other solid tumors provided little evidence efficacy. Pediatr Blood Cancer 2010;55:18–25. © 2010 Wiley-Liss, Inc.
sci-hub.se 参考文章(137)
Doreen Lemm, L.-O. Mügge, T. Mentzel, K. Höffken, Current treatment options in dermatofibrosarcoma protuberans Journal of Cancer Research and Clinical Oncology. ,vol. 135, pp. 653- 665 ,(2009) , 10.1007/S00432-009-0550-3
Yanmin Zhao, Lizhen Liu, Yingjia Wang, Gongqiang Wu, Xiaoyu Lai, Weijie Cao, Yi Luo, Yamin Tan, Jimin Shi, Wanzhuo Xie, Xiujin Ye, Zhen Cai, Maofang Lin, He Huang, Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. International Journal of Hematology. ,vol. 89, pp. 445- 451 ,(2009) , 10.1007/S12185-009-0292-7
Sonam Prakash, Lisa Sarran, Nicholas Socci, Ronald P DeMatteo, Jonathan Eisenstat, Alba M Greco, Robert G Maki, Leonard H Wexler, Michael P LaQuaglia, Peter Besmer, Cristina R Antonescu, Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. Journal of Pediatric Hematology Oncology. ,vol. 27, pp. 179- 187 ,(2005) , 10.1097/01.MPH.0000157790.81329.47
E. Buchdunger, J. Zimmermann, H. Mett, T. Meyer, M. Muller, U. Regenass, N. B. Lydon, Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 2558- 2562 ,(1995) , 10.1073/PNAS.92.7.2558
Hagop Kantarjian, Francis Giles, Lydia Wunderle, Kapil Bhalla, Susan O'Brien, Barbara Wassmann, Chiaki Tanaka, Paul Manley, Patricia Rae, William Mietlowski, Kathy Bochinski, Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jorge Cortes, Leila Alland, Oliver G. Ottmann, Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL The New England Journal of Medicine. ,vol. 354, pp. 2542- 2551 ,(2006) , 10.1056/NEJMOA055104
Mark L. Bernstein, Hits and misses in targeting pediatric cancers. Pediatric Blood & Cancer. ,vol. 52, pp. 751- 752 ,(2009) , 10.1002/PBC.21937
Aurélie Petain, Darouna Kattygnarath, Julie Azard, Etienne Chatelut, Catherine Delbaldo, Birgit Geoerger, Michel Barrois, Sophie Séronie-Vivien, Axel LeCesne, Gilles Vassal, Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults Clinical Cancer Research. ,vol. 14, pp. 7102- 7109 ,(2008) , 10.1158/1078-0432.CCR-08-0950
Yuji Sakuma, Shinji Sakurai, Sachiko Oguni, Masaaki Satoh, Mitsugu Hironaka, Ken Saito, c-kit gene mutations in intracranial germinomas Cancer Science. ,vol. 95, pp. 716- 720 ,(2004) , 10.1111/J.1349-7006.2004.TB03251.X
Grant R. Wilkinson, Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 24, pp. 475- 490 ,(1996) , 10.1007/BF02353475
H. Schmid, B. A.S. Jaeger, J. Lohse, M. Suttorp, Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib Haematologica. ,vol. 94, pp. 1177- 1179 ,(2009) , 10.3324/HAEMATOL.2009.008359